Medibase
EN VI JA

Medicines

Pricing

Drug-price declaration, winning tender prices, and the price-management framework under the 2023 Price Law and the 2024 Pharmacy Law amendment.

Overview

This section is a Vietnam-focused reference for drug-price management, declaration regimes, and the relationship between declared prices, tender prices, and reimbursement.

Scope:

  • Declared wholesale price — the new regime under the amended Pharmacy Law, declared to the Drug Administration of Vietnam (DAV).
  • Essential-medicines price declaration under the 2023 Price Law and Decree 85/2024/ND-CP — managed by the Ministry of Health, with the eligible list set out in Circular 28/2024/TT-BYT.
  • Winning tender prices — published by DAV and Vietnam Social Security; cross-reference with public-procurement rules under Circular 40/2025/TT-BYT (see Tendering & Market Access).
  • Price negotiation route — for selected high-cost or sole-source medicines; list under Circular 05/2024/TT-BYT (as amended by Circular 37/2025/TT-BYT).
  • Public price-search portals operated by DAV and the Ministry of Health transparency portal.

Important: as of 1 July 2024, the drug-pricing provisions of Decree 54/2017/ND-CP were repealed and replaced by the 2023 Price Law framework. The amended Pharmacy Law (44/2024/QH15, effective 1 July 2025) then introduced the new declared-wholesale-price regime, which runs in parallel with the Price Law's essential-medicines declaration. The two regimes use different lists and different declarants.

Key documents

Price Law framework:

  • Price Law No. 16/2023/QH15 — passed 19 June 2023, effective 1 July 2024. Replaces the 2012 Price Law (11/2012/QH13). Essential medicines used at healthcare facilities are listed in Section 9, Appendix I.
  • Decree 85/2024/ND-CP — implements the Price Law, including drug price declaration procedures. Appendix V sets out the essential medicines requiring price declaration.
  • Circular 28/2024/TT-BYT — principles and criteria for building the list of medicines required to declare prices; sets out economic and technical features and announces the list.
  • Official Dispatch 4448/BYT-QLD (1 August 2024) — DAV implementation guidance for drug price declaration under the 2023 Price Law.

Pharmacy Law framework (parallel regime):

  • Law on Pharmacy 105/2016/QH13 (Articles 107–114) — original price-management provisions.
  • Law 44/2024/QH15 (effective 1 July 2025) — introduces declared wholesale drug price; declarants are drug importers, manufacturers, and contract manufacturers; declaration goes to DAV.

Price negotiation:

  • Circular 05/2024/TT-BYT (14 May 2024) — list of drugs, medical devices, and test equipment procured through price negotiation, and supplier-selection procedures for price-negotiation packages.
  • Circular 37/2025/TT-BYT — amends and supplements Circular 05/2024/TT-BYT.

Tender pricing (cross-reference):

  • Circular 40/2025/TT-BYT — drug bidding at public medical facilities (see Tendering & Market Access).

Repealed:

  • Decree 54/2017/ND-CP — drug-pricing provisions repealed effective 1 July 2024; other provisions of the decree remain in force for non-pricing matters.

Source documents

Direct links to the official text on government portals.

Primary law:

Decree:

Operational portals:

Medibase cross-references:

  • Tender — /medicine/tendering/
  • Registration process — /medicine/registration/

Recent updates

2025 — New declared wholesale price regime: Effective 1 July 2025 under Law 44/2024/QH15, drug importers, manufacturers, and contract manufacturers must declare an "intended wholesale price" to DAV before circulation and re-declare on change. This regime runs in parallel with — and distinct from — the Price Law's essential-medicines declaration.

2025 — Price negotiation list amended: Circular 37/2025/TT-BYT amended Circular 05/2024/TT-BYT, updating the list of medicines and supplies subject to price negotiation and refining supplier-selection procedures.

2024 — Price Law regime in force: On 1 July 2024, the Price Law 16/2023/QH15 took effect together with Decree 85/2024/ND-CP. The drug-pricing provisions of Decree 54/2017/ND-CP were repealed. Circular 28/2024/TT-BYT and DAV Dispatch 4448/BYT-QLD set out the transitional implementation for medicines required to declare prices.

2024 — Price-negotiation framework consolidated: Circular 05/2024/TT-BYT (14 May 2024) consolidated the rules and lists for price-negotiation procurement, replacing fragmented earlier guidance.

Resources & links

Public price-search portals:

Government & regulator:

  • Drug Administration of Vietnam (DAV) — https://dav.gov.vn — price-declaration guidance, notices on prices deemed unreasonable, and form templates.
  • Ministry of Health (MOH) — https://moh.gov.vn.
  • Ministry of Finance — guidance on the Price Law and its decrees.

Reference & official text:

Legal basis

See the full legal register →

Page changelog

2026-06-28: Trust-infrastructure retrofit. Reflects the 2023 Price Law, the 2024 Pharmacy Law amendment (Law 44/2024/QH15 Article 107), and Decree 163/2025/ND-CP Chapter VIII which replaced the Decree 54/2017 pricing provisions repealed 1 July 2024.

Effective from:
2024-07-01
Last reviewed:
2026-06-28
Page updated:
2026-10-27

Related topics — Medicines

Regulatory Affairs

Authorization, registration, and post-market obligations under the Drug Administration of Vietnam (DAV).

Drug Registration Process in Vietnam

End-to-end analysis of marketing-authorisation workflow at the Drug Administration of Vietnam (DAV) — legal basis, dossier requirements, evaluation steps, statutory vs real-world timelines, and practical pitfalls under the amended Pharmacy Law (44/2024/QH15, in force 1 July 2025) and Circular 12/2025/TT-BYT.

Pharmacovigilance

Adverse drug reaction reporting, vaccine-safety surveillance, and risk management under the Drug Administration of Vietnam and the National DI & ADR Centre.

Pharmaceutical Distribution & Retail in Vietnam

Licensing for wholesalers, community pharmacies, drug shops, commune health-station drug cabinets, and traditional-medicine retailers under the post-1 July 2025 framework — the Pharmacy Business Eligibility Certificate, Good Distribution Practice (GDP), Good Pharmacy Practice (GPP), and Good Storage Practice (GSP), as reshaped by amended Pharmacy Law 44/2024/QH15 and Decree 163/2025/ND-CP.

Drug Import & Export in Vietnam

Two regimes — ordinary commercial trade in drugs with valid marketing authorisation, and the special import-export of drugs without registration number — under Pharmacy Law Article 60 and new Article 53a (added by Law 44/2024/QH15), Decree 163/2025/ND-CP Chapter IV, the Customs Law 54/2014/QH13, and the 1961 Hague Apostille Convention from 11 September 2026.

Clinical Trials & Bioequivalence in Vietnam

Authorisation, GCP, ethics review and BE-study requirements under Pharmacy Law Chapter XI as implemented by Decree 163/2025/ND-CP Article 23, the new Circular 50/2025/TT-BYT (effective 27 February 2026; replaces Circular 29/2018/TT-BYT, Article 9 of Circular 10/2020/TT-BYT, and Circular 08/2014/TT-BYT), Circular 43/2024/TT-BYT on ethics committees, and Circular 07/2022/TT-BYT on the BE-required substance list.

Related news — Medicine

Back to Medicines

Reference information only; not legal or medical advice.